Joseph Nixon
Financieel Directeur/CFO bij Locus Biosciences, Inc.
Profiel
Joseph Nixon is currently the Director at Bioaesthetics Corp.
and the Chief Financial Officer at Locus Biosciences, Inc. He received his undergraduate degree from Case Western Reserve University and his MBA from Harvard Business School.
Actieve functies van Joseph Nixon
| Bedrijven | Functie | Begin |
|---|---|---|
Bioaesthetics Corp.
 Bioaesthetics Corp. Miscellaneous Commercial ServicesCommercial Services Bioaesthetics Corp. provides biotechnology health care services. The company was founded by Nicholas C. Pashos and is headquartered in New Orleans, LA. | Directeur/Bestuurslid | 23-08-2023 |
Locus Biosciences, Inc.
 Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Financieel Directeur/CFO | - |
Opleiding van Joseph Nixon
| Case Western Reserve University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Bioaesthetics Corp.
Bioaesthetics Corp. Miscellaneous Commercial ServicesCommercial Services Bioaesthetics Corp. provides biotechnology health care services. The company was founded by Nicholas C. Pashos and is headquartered in New Orleans, LA. | Commercial Services |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
